ANTHEM Share Price | Anthem Biosciences Ltd Stock Analysis & Recommendation

Q: Is Anthem Bioscienc overvalued or undervalued?

As of 29 August 2025, the valuation grade for Anthem Bioscienc has moved from does not qualify to very expensive, indicating a significant shift in its perceived value. The company is currently overvalued, with a PE ratio of 90.82, a Price to Book Value of 18.59, and an EV to EBITDA ratio of 65.82. These ratios are considerably higher than its peers, such as Sun Pharma with a PE of 33.34 and Divi's Lab at 70.28, both of which are categorized as expensive or very expensive.In comparison to other companies in the pharmaceuticals and biotechnology sector, Anthem Bioscienc's high valuation metrics suggest that investors are paying a premium for its stock. The PEG ratio is notably at 0.00, which raises concerns about growth expectations not being met. While the stock has shown a positive return of 4.51% over the past month compared to a decline in the Sensex, the overall valuation still points to an overvaluation scenario.

Q: How has been the historical performance of Anthem Bioscienc?

Answer:The historical performance of Anthem Bioscienc shows significant growth in various financial metrics from March 2024 to March 2025.Breakdown:Anthem Bioscienc reported net sales of 1,844.55 Cr in March 2025, an increase from 1,419.37 Cr in March 2024. The total operating income also rose to 1,844.55 Cr from 1,419.37 Cr, while total expenditure increased to 1,173.72 Cr from 914.40 Cr. This led to an operating profit (PBDIT) of 756.56 Cr, up from 568.67 Cr the previous year. Profit before tax reached 656.87 Cr, compared to 477.32 Cr in the prior year, resulting in a profit after tax of 451.26 Cr, which was higher than 367.31 Cr in March 2024. The earnings per share increased to 8.07 from 6.57, and the operating profit margin improved slightly to 36.37% from 35.58%. On the balance sheet, total assets grew to 2,789.64 Cr from 2,356.72 Cr, while total liabilities also increased to 2,789.64 Cr from 2,356.72 Cr. The cash flow from operating activities saw a notable rise to 418.00 Cr from 140.00 Cr, contributing to a net cash inflow of 132.00 Cr, reversing the outflow of 158.00 Cr in the previous year. Overall, Anthem Bioscienc demonstrated robust growth in sales, profits, and cash flow, indicating a strong financial performance.

Q: Why is Anthem Biosciences Ltd falling/rising?

As of 27-Jan, Anthem Biosciences Ltd's stock price is falling, currently at Rs. 596.00, which reflects a decrease of Rs. 13.25 or 2.17%. The stock has underperformed compared to the sector by 1.84% today and has reached a new 52-week low of Rs. 585.7. This decline follows a trend reversal after two consecutive days of gains, indicating a shift in market sentiment.The stock's performance over the past week shows a decrease of 0.65%, while it has fallen 8.87% over the past month, significantly underperforming the Sensex, which has only declined by 3.74% in the same period. Year-to-date, the stock is down 8.46%, again worse than the Sensex's decline of 3.95%. Additionally, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, suggesting a bearish trend. There has also been a notable drop in investor participation, with delivery volume decreasing by 16.3% compared to the 5-day average. This combination of factors contributes to the stock's current downward trajectory.

Upcoming Result: Anthem Bioscienc will declare its result soon on 05 Feb 2026

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

1.21 lacs (-40.26%) Volume

Shareholding (Dec 2025)

FII

1.36%

Held by 48 FIIs

DII

0.27%

Held by 20 DIIs

Promoter

74.69%

Is Anthem Bioscienc overvalued or undervalued?

01-Sep-2025

As of August 29, 2025, Anthem Bioscienc is considered very expensive with a PE ratio of 90.82 and other high valuation metrics, indicating it is overvalued compared to peers, despite a recent positive return of 4.51%.

View full answer

How has been the historical performance of Anthem Bioscienc?

09-Nov-2025

Anthem Bioscienc experienced significant growth from March 2024 to March 2025, with net sales rising to 1,844.55 Cr and profit after tax increasing to 451.26 Cr. Key metrics such as operating profit and cash flow also improved, reflecting strong financial performance.

View full answer

Why is Anthem Biosciences Ltd falling/rising?

28-Jan-2026

As of 27-Jan, Anthem Biosciences Ltd's stock price is Rs. 596.00, down 2.17% and at a new 52-week low. The stock has underperformed the sector and major indices, indicating a bearish trend with decreased investor participation.

View full answer

Which are the latest news on Anthem Bioscienc?

28-Jan-2026

How has been the historical performance of Anthem Bioscienc?

When is the next results date for Anthem Biosciences Ltd?

28-Jan-2026

The next results date for Anthem Biosciences Ltd is February 5, 2026.

View full answer

Compare Anthem Bioscienc with Similar Stocks

Ipca Labs Ajanta Pharma Glaxosmi. Pharma

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

INR 33,764 Cr (Large Cap)

P/E

67.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.34

Return on Equity

17.74%

Price to Book

11.73

Revenue and Profits:

Net Sales:

550 Cr

(Quarterly Results - Sep 2025)

Net Profit:

173 Cr

Total Returns

Total Returns (Price + Dividend)

Dividend Yield (0%)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-15.77%

6 Months

-20.48%

1 Year

0.0%

2 Years

0.0%

3 Years

0.0%

4 Years

0.0%

5 Years

0.0%

Anthem Bioscienc for the last several years.

Risk Adjusted Returns v/s

Returns Beta

Beta has not been calculated since enough price history is not available

News & Corporate Actions

News

When is the next results date for Anthem Biosciences Ltd?

The next results date for Anthem Biosciences Ltd is scheduled for February 5, 2026....

Read full news article

How has been the historical performance of Anthem Bioscienc?

Answer: The historical performance of Anthem Bioscienc shows significant growth in various financial metrics from March 2024 to March 2025. Breakdown: Anthem Bioscienc reported net sales of 1,844.55 Cr in March 2025, an increase from 1,419.37 Cr in March 2024. The total operating income also rose to 1,844.55 Cr from 1,419.37 Cr, while total expenditure increased to 1,173.72 Cr from 914.40 Cr. This led to an operating profit (PBDIT) of 756.56 Cr, up from 568.67 Cr the previous year. Profit before tax reached 656.87 Cr, compared to 477.32 Cr in the prior year, resulting in a profit after tax of 451.26 Cr, which was higher than 367.31 Cr in March 2024. The earnings per share increased to 8.07 from 6.57, and the operating profit margin improved slightly to 36.37% from 35.58%. On the balance sheet, total assets grew to 2,789.64 Cr from 2,356.72 Cr, while total liabilities also increased to 2,789.64 Cr from 2,35...

Read full news article

Announcements

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

27-Jan-2026 | Source : BSE

Pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to inform you that an Earnings Conference Call to discuss the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31 2025 is scheduled on Thursday February 05 2026 at 02:30 PM IST/ 04:00 AM USA / 09:00 AM UK / 05:00 PM SGT/HKT.

Board Meeting Intimation for Board Meeting Intimation For Approval Of Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2025

27-Jan-2026 | Source : BSE

Anthem Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/02/2026 inter alia to consider and approve This is to inform you that pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 a meeting of the Board of Directors of Anthem Biosciences Limited (the Company) is scheduled to be held on Thursday February 05 2026 inter alia to consider and approve the Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31 2025.

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

27-Jan-2026 | Source : BSE

Revised Earnings Conference Call to discuss the unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31 2025

Corporate Actions

BOARD MEETING

05 Feb 2026

DIVIDEND

No Dividend history available

SPLITS

No Splits history available

BONUS

No Bonus history available

RIGHTS

No Rights history available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

29.80%

EBIT Growth (5y)

44.32%

EBIT to Interest (avg)

56.77

Debt to EBITDA (avg)

0.16

Net Debt to Equity (avg)

-0.25

Sales to Capital Employed (avg)

0.62

Tax Ratio

28.85%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

8.96%

ROCE (avg)

32.59%

ROE (avg)

19.93%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

11.82

EV to EBIT

53.61

EV to EBITDA

47.54

EV to Capital Employed

17.47

EV to Sales

17.80

PEG Ratio

Dividend Yield

ROCE (Latest)

32.59%

ROE (Latest)

17.74%

Technicals key factors

Indicator

Weekly

Monthly

No records

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 22 Schemes (6.89%)

FIIs

Held by 48 FIIs (1.36%)

Promoter with highest holding

Ajay Bhardwaj (42.53%)

Highest Public shareholder

Viridity Tone Llp (3.8%)

Individual Investors Holdings

9.6%

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Sep'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is 2.64% vs 12.32% in Jun 2025",
        "dir": -1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is 33.77% vs 21.03% in Jun 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Jun'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "552.23",
          "val2": "538.01",
          "chgp": "2.64%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "225.66",
          "val2": "195.43",
          "chgp": "15.47%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "2.23",
          "val2": "1.61",
          "chgp": "38.51%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "198.43",
          "val2": "148.34",
          "chgp": "33.77%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "40.86%",
          "val2": "36.32%",
          "chgp": "4.54%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Standalone) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,090.24",
          "val2": "863.40",
          "chgp": "26.27%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "421.08",
          "val2": "324.04",
          "chgp": "29.95%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "3.84",
          "val2": "5.20",
          "chgp": "-26.15%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "346.77",
          "val2": "255.63",
          "chgp": "35.65%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "38.62%",
          "val2": "37.53%",
          "chgp": "1.09%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Standalone) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,342.38",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "522.15",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Interest",
          "val1": "7.30",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "378.19",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "38.90%",
          "val2": "NA%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Standalone) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,840.65",
          "val2": "1,417.54",
          "chgp": "29.85%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "689.01",
          "val2": "504.89",
          "chgp": "36.47%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "9.09",
          "val2": "9.14",
          "chgp": "-0.55%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "506.19",
          "val2": "374.78",
          "chgp": "35.06%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "37.43%",
          "val2": "35.62%",
          "chgp": "1.81%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Standalone) - Sep'25 - QoQ

Sep'25

Jun'25

Change(%)

Net Sales

552.23

538.01

2.64%

Operating Profit (PBDIT) excl Other Income

225.66

195.43

15.47%

Interest

2.23

1.61

38.51%

Exceptional Items

0.00

Standalone Net Profit

198.43

148.34

33.77%

Operating Profit Margin (Excl OI)

40.86%

36.32%

4.54%

Values in Rs Cr.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Sep 2025 is 2.64% vs 12.32% in Jun 2025

Standalone Net Profit

QoQ Growth in quarter ended Sep 2025 is 33.77% vs 21.03% in Jun 2025

All Quarterly Results

Half Yearly Results Snapshot (Standalone) - Sep'25

Sep'25

Sep'24

Change(%)

Net Sales

1,090.24

863.40

26.27%

Operating Profit (PBDIT) excl Other Income

421.08

324.04

29.95%

Interest

3.84

5.20

-26.15%

Exceptional Items

0.00

Standalone Net Profit

346.77

255.63

35.65%

Operating Profit Margin (Excl OI)

38.62%

37.53%

1.09%

Values in Rs Cr.

Compare with Peers

Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

All Half Yearly Results

Nine Monthly Results Snapshot (Standalone) - Mar'25

Mar'25

Change(%)

Net Sales

1,342.38

Operating Profit (PBDIT) excl Other Income

522.15

Interest

7.30

Exceptional Items

0.00

Standalone Net Profit

378.19

Operating Profit Margin (Excl OI)

38.90%

NA%

Values in Rs Cr.

Compare with Peers

Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

All Nine Monthly Results

Annual Results Snapshot (Standalone) - Mar'25

Mar'25

Mar'24

Change(%)

Net Sales

1,840.65

1,417.54

29.85%

Operating Profit (PBDIT) excl Other Income

689.01

504.89

36.47%

Interest

9.09

9.14

-0.55%

Exceptional Items

0.00

Standalone Net Profit

506.19

374.78

35.06%

Operating Profit Margin (Excl OI)

37.43%

35.62%

1.81%

Values in Rs Cr.

Compare with Peers

Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

All Annual Results

Company CV

About Anthem Biosciences Ltd

Anthem Biosciences Ltd

Large Cap

Pharmaceuticals & Biotechnology

Anthem Biosciences Limited was originally incorporated as "Anthem Biosciences Private Limited", dated June 13, 2006, issued by RoC. Subsequently, Company was converted from a Private Company to a Public Company , followed by the change in name of the Company to "Anthem Biosciences Limited" and a Certificate of Incorporation upon the conversion was issued by RoC on December 10, 2024.

Company Coordinates

No Company Details Available

Anthem Bioscienc

1Day

52 Week

CASH

FII

DII

Promoter

Is Anthem Bioscienc overvalued or undervalued?

Watch in Real-Time

How has been the historical performance of Anthem Bioscienc?

Why is Anthem Biosciences Ltd falling/rising?

Which are the latest news on Anthem Bioscienc?

When is the next results date for Anthem Biosciences Ltd?

Compare Anthem Bioscienc with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

Returns Beta

News

When is the next results date for Anthem Biosciences Ltd?

How has been the historical performance of Anthem Bioscienc?

Announcements

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Board Meeting Intimation for Board Meeting Intimation For Approval Of Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2025

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Standalone) - Sep'25 - QoQ

Half Yearly Results Snapshot (Standalone) - Sep'25

Nine Monthly Results Snapshot (Standalone) - Mar'25

Annual Results Snapshot (Standalone) - Mar'25

About Anthem Biosciences Ltd

Company Coordinates